SPC512

Belzútifan eða lyfjafræðilega viðunandi salt þar af, sérstakleg belzútifan / Belzutifan, or a pharmaceutically acceptable salt thereof, particularly belzutifan

  • Status:
    Umsókn
  • Application date:
    6.5.2025
  • Application published:
    1.6.2025
  • Medicine name:
    Welireg
  • Medicine for children:
    No

Timeline

Today
6.5.2025Application
1.6.2025Publication

Marketing license

    • Foreign authorization number:
      EU/1/24/1893
    • Date:
      12.2.2025

    Owner

    • Name:
      Peloton Therapeutics, Inc.
    • Address:
      2330 Inwood Road Suite 226, Dallas, TX 75235-7323 US

    Agent

    • Name:
      Árnason Faktor ehf.
    • Address:
      Guðríðarstíg 2-4, 113 Reykjavík

    Patent

    Upload documents